文献速递糖尿病骨质疏松与钙磷/甲状旁腺

卡格列净与2型糖尿病患者骨折风险:CANVAS项目结果

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
PubMed 文献 · Diabetologia · 2019-08-10

CANVAS项目分析显示,卡格列净组骨折发生率高于安慰剂组(15.40 vs 11.93/1000患者年;HR 1.26 [95%CI 1.04,1.52]),且CANVAS与CANVAS-R两试验间存在显著异质性(p=0.005)。基线特征、剂量、随访时间及跌倒相关不良事件均未能明确解释该异质性。CREDENCE试验的阴性结果提示CANVAS中的关联可能为偶然发现。

要点

  • 卡格列净组骨折风险较安慰剂组升高26%(HR 1.26,95%CI 1.04–1.52)。
  • CANVAS与CANVAS-R试验间骨折风险异质性显著(p=0.005)。
  • 异质性无法用基线特征、剂量、随访或跌倒事件解释。

核心结论

  • CANVAS项目中卡格列净与骨折风险升高相关,但两试验间异质性无法明确解释。
  • CREDENCE试验的阴性结果提示CANVAS中的关联可能为偶然发现。

研究设计与样本

  • 对CANVAS和CANVAS-R两项高度相似试验的分析,共纳入10142例有心血管病史或高危的2型糖尿病患者。
  • 受试者随机接受卡格列净(100/300 mg每日一次合并)或安慰剂。

主要发现

  • 496例参与者记录到至少1次骨折事件,卡格列净组与安慰剂组发生率分别为15.40和11.93/1000患者年(HR 1.26 [95%CI 1.04,1.52])。
  • CANVAS试验(n=4330)骨折HR为1.55(95%CI 1.21,1.97),CANVAS-R试验(n=5812)为0.86(95%CI 0.62,1.19),异质性p=0.005。
  • 基线特征、随机治疗与参与者特征的交互作用、剂量效应、随访时长、代谢效应、跌倒相关不良事件均未明确解释异质性。

临床怎么用

  • 对于2型糖尿病合并心血管病或高危患者,使用卡格列净时应关注骨折风险,尤其参考CANVAS试验结果。
  • 两试验异质性及CREDENCE阴性结果提示需结合整体证据评估骨折风险,避免仅凭CANVAS关联做出临床决策。

局限性

  • 分析为对两项试验的事后分析,骨折风险异质性原因未能明确解释。
  • CREDENCE试验结果仅作为外部参考,未在本分析中直接验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: An increased risk of fracture with canagliflozin vs placebo was reported from the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, with heterogeneity of findings identified between the two trials that comprise the CANVAS Program, CANVAS and CANVAS-R. The objective of these analyses was to identify reasons for the possibly different effects on fracture observed between CANVAS and CANVAS-R. METHODS: This study was an analysis of two highly similar trials, CANVAS and CANVAS-R, conducted in 10,142 individuals with type 2 diabetes and history or high risk of cardiovascular disease who received canagliflozin (pooled 100/300 mg once daily) or placebo. Outcomes assessed in this analysis were effects on adjudicated fractures overall and by type, location, association with a fall, dose and follow-up time. RESULTS: A total of 496 participants recorded ≥1 fracture event during follow-up (15.40 vs 11.93 per 1000 patient-years with canagliflozin vs placebo; HR 1.26 [95% CI 1.04, 1.52]). There was significant heterogeneity in the effects on fracture (p = 0.005) between CANVAS (n = 4330: HR 1.55 [95% CI 1.21, 1.97]) and CANVAS-R (n = 5812: HR 0.86 [95% CI 0.62, 1.19]). The between-study heterogeneity in fracture risk was not clearly explained by differences in baseline characteristics, interactions of randomised treatment with participant characteristics, dose effects, duration of follow-up, metabolic effects, adverse events related to falls or adverse events possibly causing falls. CONCLUSIONS/INTERPRETATION: There was no evidence to explain clearly the fracture risk observed in the CANVAS Program or the heterogeneity in fracture risk between the two studies. The recently reported null result for fracture in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial suggests that the observed association in CANVAS is likely to be a chance finding, although an unidentified fall-related mechanism remains a possibility. TRIAL REGISTRATION: ClinicalTrials.gov NCT01032629, NCT01989754.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Zhou Z, Jardine M, Perkovic V, et al. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 2019. PMID: 31399845. doi:10.1007/s00125-019-4955-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。